December 06, 2017

EP Vantage 2018 Preview – M&A and investor money to drive sector in 2018

October 05, 2017

Back to the future for small caps, but not all benefit

Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.

September 27, 2017

Interview – Next from Autolus, cracking tolerance and solid tumours

September 18, 2017

Autolus takes its first baby steps into the clinic

September 08, 2017

CAR-TCR Summit: Industry and patients clash on cell therapy cost

September 01, 2017

Macrogenics and J&J fallout could spell double trouble

August 31, 2017

Everything is negotiable with Novartis’s $475K Kymriah price

August 30, 2017

World’s first CAR-T approval sweeps away more cell therapy doubts

August 29, 2017

For Gilead Kite is no Pharmasset